Answers are grounded in this paper and cite their sources.
Background: Aesthetic procedures such as laser resurfacing, microneedling, and injectable treatments intentionally disrupt the skin barrier, increasing susceptibility to microbial colonization, inflammation, and delayed healing. Post-procedural care therefore requires biomaterials that provide antimicrobial protection while supporting controlled inflammation and tissue regeneration. Observation: Chitosan, a naturally derived polysaccharide, exhibits a unique combination of antimicrobial activity, immunomodulatory effects, and wound-healing support. These properties are influenced by molecular weight, degree of deacetylation, and formulation, allowing chitosan to function as a barrier material, bioactive dressing, and drug-delivery platform in aesthetic settings. Due to its ultra-low molecular weight (below 600 Da), Ideal Size Chitosan (ISC) manufactured by Arche (Doum Inc., Korea) is topically effective, as it can penetrate the skin barrier to target deeper dermal layers and deliver enhanced bioactive effects. Clinical relevance: In post-aesthetic care, chitosan-based films, hydrogels, and nanoparticles may reduce infection risk, modulate excessive inflammatory responses, and promote re-epithelialization. However, variability among chitosan formulations and limited procedure-specific clinical data remain important considerations. Conclusion: This short communication highlights the rationale for using chitosan as a multifunctional biomaterial in aesthetic aftercare and underscores the need for standardized formulations and targeted clinical studies.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: